Evotec's Compound Collection

Evotec’s screening library is differentiated by its quality, diversity and novelty. It has a confirmed track record for delivering high-quality, diverse and tractable hit compounds for medicinal chemistry optimization.

• Over 850,000 IP-free lead-like compounds
  • 800,000 maximally diverse compounds including 50,000 ‘ligand efficiency’ compounds
  • 25,000 fragments
  • 5,000 compounds with known bio-annotation
  • 30,000 natural products and semi-synthetic derivatives
  • 2,000 macrocycles
  • 5,000 Cys directed covalent library
  • 1,200 RNA-focussed binders
• Carefully curated to fuel groundbreaking discoveries
• Single and pooled compound libraries optimized for Affinity Selection Mass Spectrometry (ASMS) screening
• Through collaboration with X-Chem, access to over 150 billion drug-like compounds from X-Chem’s diverse collections of non-covalent and covalent DNA-encoded libraries
• Access to 48 million commercial compounds available through 800+ catalogues of global suppliers
• Rapid access to >70 billion on-demand ‘synthetically accessible’ compounds

Evotec can also screen:

• Customer libraries of any size
• Virtual screening derived hits
• Smaller, more target-directed libraries

Evotec’s high-quality collection of >850,000 compounds exhibits a high degree of drug-likeness as assessed by QED score and other physicochemical
properties, ensuring the best possible chance of success.

Maintaining quality is vital to ensure the generation of high-quality screening data. In addition to characterizing new compounds added to the collection, routine quality control is performed on our compound collection to ensure quality over time.

These include:

• Confirmation of compound integrity/identity by mass spectrometry

• Purity assessment: UV-purity detection at 215 nm (optionally expanded to 200–400 nm) and, if required, ELSD detection